secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001437749-23-031390
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports Q3 2023 cash of $24.6M; advances Annamycin in AML and STS
---------------------------------------------------------------------------

- Cash and equivalents $24.6M as of Sep 30, 2023; runway estimated into Q3 2024.
- R&D expense $3.3M, down 45% YoY from $6.0M; G&A $2.6M, down 16% from $3.1M.
- Dosed first subjects in Phase 2 trial of Annamycin + Cytarabine for AML (MB106).
- Completed enrollment in U.S. Phase 1b/2 trial of Annamycin for STS lung metastases (MB107).
- Independent assessment confirmed absence of cardiotoxicity in Annamycin-treated subjects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/0001437749-23-031390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923031390/mbrx20231109_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer